CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has been effective faithfully but unsuccessfully to develop an one off therapy, variously referred to as Pro 140, leronlimab, as well as Vyrologix.

In development of this particular treatment, CytoDyn has cast its net far and wide both geographically and in terms of prospective indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll actually be used is an open question.

While CYDY  is actually dawdling, market opportunities for leronlimab as a combination treatment in the therapy of multi-drug-resistant HIV are actually closing.

I’m creating my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale of the last several shares of mine. The 1st CytoDyn post of mine, “CytoDyn: What to be able to Do When It’s Too Good In order to Be True?”, set away the following prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan offered such an extremely promotional image in the Uptick Newswire interview that I came away with a poor opinion of the company.

Irony of irony, my bad opinion of the business has grown steadily, yet the disappointment has not been financial. Two many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > 6 bagger at the moment still disappoints? Therein lies the story; permit me to explain.

CytoDyn acquired its much storied therapy (which I shall relate to as leronlimab) back during 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor of the treatment as well as avoidance of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti-viral activity in HIV- infected subjects. Today’s transaction of $3.5 huge number of transfers ownership of this expertise and associated intellectual property coming from Progenics to CytoDyn, and roughly 25 million mg of majority drug substance…. milestone payments upon commencement of a level III clinical trial ($1.5 million) and the first new drug application approval ($5 million), and even royalty payments of 5 percent of net sales after commercialization.

Since that time, CytoDyn’s leading nous, Nader Pourhassan [NP] has turned this inauspicious acquisition right into a springboard for CytoDyn to buy a sector cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with multiple indications and many therapies, it’s this single treatment as well as a “broad pipeline of indications” as it places it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a likely beneficial therapy of dozens of indications.

The opening banner of its on the website of its (below) shows an energetic organization with diverse interests albeit centered on leronlimab, several illness types, multiple delivering presentations and multiple publications.

Can it all be smoke and mirrors? That’s a question I have been asking myself from the really beginning of the interest of mine in this particular company. Judging with the multiples of thousands of several responses on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I’m much from alone in this question.

CytoDyn is a classic battleground, or perhaps some may say cult stock. Its adherents are fiercely shielding of its prospects, quick to label some negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News